Ansulin 30/70 100IU/ml (10ml) Inj
Indication: Type 1 and Type 2 Diabetes Mellitus. Dosage & Administration The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. PHARMACOLOGY Ansulin® is human insulin made by DNA recombinant technology so it has the same structure and function as natural insulin. The product can regulate the glucose metabolism and stimulate the ingestion and utilization of glucose by liver, muscles, and fat tissue. It can accelerate the transformation from glucose to glycogen stored in muscles and liver and inhibit the gluconeogenesis, thus, to lower the blood glucose. Normally, Ansulin® R takes effect within 30 minutes after injection, reaches its peak within 1-3 hours and lasts about 4-8 hours. On the other hand, Ansulin® N comes into effect slowly after injection, reaches its peak within 6-9 hours & lasts about 24 hours. Ansulin® 30/70 & Ansulin® 50/50 take effect within 30 minutes after injection, reach their peaks within 2-8 hours and last about 24 hours. USAGE 1. Ansulin® should be injected subcutaneously 15 minutes to one hour before meal. The exact time for administration is suggested by doctors with regard to each individual's case. 2. Prepare before use Firstly, clean your hands. Shake or rotate the vial gently to mix the solution uniformly and check if the insulin has the normal appearance. If using a new Ansulin® bottle then flip off the plastic protective cap and wipe the rubber stopper with an alcohol swab. Draw air into your syringe equal to the amount of insulin needed. Puncture the needle into the vial and inject the air. Turn the bottle and syringe upside down. Withdraw correct dose of insulin into the syringe. Before pulling out the needle, check if there are any bubbles remain in the syringe. If so, put the syringe upright and tap the syringe to discharge the air bubbles. 3. Injection Site Choose the area where skin is less tight, such as the upper arm, thigh, buttock and abdomen, etc. To avoid tissue damage, choose a site for each injection that is at least 1 cm from the previous injection site. 4. Injection Method Cleanse the skin with alcohol where the injection is to be made. Put the needle in such a position as to form 45° angle with the skin. Puncture the needle into skin and inject insulin. Then pull the needle out and apply gentle pressure over the injected site for several seconds. Do not rub the injection site. DOSAGE The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor's instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. ADVERSE EFFECT Hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. Few cases of the allergic reaction such as red and swollen or itching are reported. It usually disappears in a few days. In some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. CONTRAINDICATION Hypoglycemia or the patients who have allergic reaction to insulin or any of the excipients. PRECAUTION Inadequate dosing or discontinuation especially in type 1 diabetes, may lead to hyperglycemia. Hypoglycemia may occur if the insulin dose is too high in relation to the insulin requirement. Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycemia. PREGNANCY AND LACTATION There are no restrictions on treatment of diabetes with insulin during pregnancy, as ..
Tk.415.00/=
Ansulin 30/70 40IU (10ml) Injection
Indication: Type 1 and Type 2 Diabetes Mellitus.Dosage & AdministrationThe dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.PHARMACOLOGYAnsulin® is human insulin made by DNA recombinant technology so it has the same structure and function as natural insulin. The product can regulate the glucose metabolism and stimulate the ingestion and utilization of glucose by liver, muscles, and fat tissue. It can accelerate the transformation from glucose to glycogen stored in muscles and liver and inhibit the gluconeogenesis, thus, to lower the blood glucose. Normally, Ansulin® R takes effect within 30 minutes after injection, reaches its peak within 1-3 hours and lasts about 4-8 hours. On the other hand, Ansulin® N comes into effect slowly after injection, reaches its peak within 6-9 hours & lasts about 24 hours. Ansulin® 30/70 & Ansulin® 50/50 take effect within 30 minutes after injection, reach their peaks within 2-8 hours and last about 24 hours.USAGE1. Ansulin® should be injected subcutaneously 15 minutes to one hour before meal. The exact time for administration is suggested by doctors with regard to each individual's case.2. Prepare before use Firstly, clean your hands. Shake or rotate the vial gently to mix the solution uniformly and check if the insulin has the normal appearance.If using a new Ansulin® bottle then flip off the plastic protective cap and wipe the rubber stopper with an alcohol swab. Draw air into your syringe equal to the amount of insulin needed. Puncture the needle into the vial and inject the air. Turn the bottle and syringe upside down. Withdraw correct dose of insulin into the syringe. Before pulling out the needle, check if there are any bubbles remain in the syringe. If so, put the syringe upright and tap the syringe to discharge the air bubbles.3. Injection Site Choose the area where skin is less tight, such as the upper arm, thigh, buttock and abdomen, etc. To avoid tissue damage, choose a site for each injection that is at least 1 cm from the previous injection site.4. Injection Method Cleanse the skin with alcohol where the injection is to be made. Put the needle in such a position as to form 45° angle with the skin. Puncture the needle into skin and inject insulin. Then pull the needle out and apply gentle pressure over the injected site for several seconds. Do not rub the injection site.DOSAGEThe dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor's instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.ADVERSE EFFECTHypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. Few cases of the allergic reaction such as red and swollen or itching are reported. It usually disappears in a few days. In some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique.CONTRAINDICATIONHypoglycemia or the patients who have allergic reaction to insulin or any of the excipients.PRECAUTIONInadequate dosing or discontinuation especially in type 1 diabetes, may lead to hyperglycemia. Hypoglycemia may occur if the insulin dose is too high in relation to the insulin requirement. Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycemia.PREGNANCY AND LACTATIONThere are no restrictions on treatment of diabetes with insulin during pregnancy, as insulin does not pass the placental barrier. Insulin treatment of the nursing mother presents no risk to the baby.DRUG INTERACTIONWhen using oral contracep..
Tk.195.00/=
Ansulin 50/50 100IU Inj
Indication: Type 1 and Type 2 Diabetes Mellitus. Dosage & Administration The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. PHARMACOLOGY Ansulin® is human insulin made by DNA recombinant technology so it has the same structure and function as natural insulin. The product can regulate the glucose metabolism and stimulate the ingestion and utilization of glucose by liver, muscles, and fat tissue. It can accelerate the transformation from glucose to glycogen stored in muscles and liver and inhibit the gluconeogenesis, thus, to lower the blood glucose. Normally, Ansulin® R takes effect within 30 minutes after injection, reaches its peak within 1-3 hours and lasts about 4-8 hours. On the other hand, Ansulin® N comes into effect slowly after injection, reaches its peak within 6-9 hours & lasts about 24 hours. Ansulin® 30/70 & Ansulin® 50/50 take effect within 30 minutes after injection, reach their peaks within 2-8 hours and last about 24 hours. USAGE 1. Ansulin® should be injected subcutaneously 15 minutes to one hour before meal. The exact time for administration is suggested by doctors with regard to each individual's case. 2. Prepare before use Firstly, clean your hands. Shake or rotate the vial gently to mix the solution uniformly and check if the insulin has the normal appearance. If using a new Ansulin® bottle then flip off the plastic protective cap and wipe the rubber stopper with an alcohol swab. Draw air into your syringe equal to the amount of insulin needed. Puncture the needle into the vial and inject the air. Turn the bottle and syringe upside down. Withdraw correct dose of insulin into the syringe. Before pulling out the needle, check if there are any bubbles remain in the syringe. If so, put the syringe upright and tap the syringe to discharge the air bubbles. 3. Injection Site Choose the area where skin is less tight, such as the upper arm, thigh, buttock and abdomen, etc. To avoid tissue damage, choose a site for each injection that is at least 1 cm from the previous injection site. 4. Injection Method Cleanse the skin with alcohol where the injection is to be made. Put the needle in such a position as to form 45° angle with the skin. Puncture the needle into skin and inject insulin. Then pull the needle out and apply gentle pressure over the injected site for several seconds. Do not rub the injection site. DOSAGE The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor's instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. ADVERSE EFFECT Hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. Few cases of the allergic reaction such as red and swollen or itching are reported. It usually disappears in a few days. In some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. CONTRAINDICATION Hypoglycemia or the patients who have allergic reaction to insulin or any of the excipients. PRECAUTION Inadequate dosing or discontinuation especially in type 1 diabetes, may lead to hyperglycemia. Hypoglycemia may occur if the insulin dose is too high in relation to the insulin requirement. Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycemia. PREGNANCY AND LACTATION There are no restrictions on treatment of diabetes with insulin during pregnancy, as ..
Tk.415.00/=
Ansulin N 100 IU
Indication: Type 1 and Type 2 Diabetes Mellitus. Dosage & Administration The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. PHARMACOLOGY Ansulin® is human insulin made by DNA recombinant technology so it has the same structure and function as natural insulin. The product can regulate the glucose metabolism and stimulate the ingestion and utilization of glucose by liver, muscles, and fat tissue. It can accelerate the transformation from glucose to glycogen stored in muscles and liver and inhibit the gluconeogenesis, thus, to lower the blood glucose. Normally, Ansulin® R takes effect within 30 minutes after injection, reaches its peak within 1-3 hours and lasts about 4-8 hours. On the other hand, Ansulin® N comes into effect slowly after injection, reaches its peak within 6-9 hours & lasts about 24 hours. Ansulin® 30/70 & Ansulin® 50/50 take effect within 30 minutes after injection, reach their peaks within 2-8 hours and last about 24 hours. USAGE 1. Ansulin® should be injected subcutaneously 15 minutes to one hour before meal. The exact time for administration is suggested by doctors with regard to each individual's case. 2. Prepare before use Firstly, clean your hands. Shake or rotate the vial gently to mix the solution uniformly and check if the insulin has the normal appearance. If using a new Ansulin® bottle then flip off the plastic protective cap and wipe the rubber stopper with an alcohol swab. Draw air into your syringe equal to the amount of insulin needed. Puncture the needle into the vial and inject the air. Turn the bottle and syringe upside down. Withdraw correct dose of insulin into the syringe. Before pulling out the needle, check if there are any bubbles remain in the syringe. If so, put the syringe upright and tap the syringe to discharge the air bubbles. 3. Injection Site Choose the area where skin is less tight, such as the upper arm, thigh, buttock and abdomen, etc. To avoid tissue damage, choose a site for each injection that is at least 1 cm from the previous injection site. 4. Injection Method Cleanse the skin with alcohol where the injection is to be made. Put the needle in such a position as to form 45° angle with the skin. Puncture the needle into skin and inject insulin. Then pull the needle out and apply gentle pressure over the injected site for several seconds. Do not rub the injection site. DOSAGE The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor's instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. ADVERSE EFFECT Hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. Few cases of the allergic reaction such as red and swollen or itching are reported. It usually disappears in a few days. In some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. CONTRAINDICATION Hypoglycemia or the patients who have allergic reaction to insulin or any of the excipients. PRECAUTION Inadequate dosing or discontinuation especially in type 1 diabetes, may lead to hyperglycemia. Hypoglycemia may occur if the insulin dose is too high in relation to the insulin requirement. Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycemia. PREGNANCY AND LACTATION There are no restrictions on treatment of diabetes with insulin during pregnancy, as ..
Tk.415.00/=
Ansulin N 40 IU
Indication: Type 1 and Type 2 Diabetes Mellitus. Dosage & Administration The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. PHARMACOLOGY Ansulin® is human insulin made by DNA recombinant technology so it has the same structure and function as natural insulin. The product can regulate the glucose metabolism and stimulate the ingestion and utilization of glucose by liver, muscles, and fat tissue. It can accelerate the transformation from glucose to glycogen stored in muscles and liver and inhibit the gluconeogenesis, thus, to lower the blood glucose. Normally, Ansulin® R takes effect within 30 minutes after injection, reaches its peak within 1-3 hours and lasts about 4-8 hours. On the other hand, Ansulin® N comes into effect slowly after injection, reaches its peak within 6-9 hours & lasts about 24 hours. Ansulin® 30/70 & Ansulin® 50/50 take effect within 30 minutes after injection, reach their peaks within 2-8 hours and last about 24 hours. USAGE 1. Ansulin® should be injected subcutaneously 15 minutes to one hour before meal. The exact time for administration is suggested by doctors with regard to each individual's case. 2. Prepare before use Firstly, clean your hands. Shake or rotate the vial gently to mix the solution uniformly and check if the insulin has the normal appearance. If using a new Ansulin® bottle then flip off the plastic protective cap and wipe the rubber stopper with an alcohol swab. Draw air into your syringe equal to the amount of insulin needed. Puncture the needle into the vial and inject the air. Turn the bottle and syringe upside down. Withdraw correct dose of insulin into the syringe. Before pulling out the needle, check if there are any bubbles remain in the syringe. If so, put the syringe upright and tap the syringe to discharge the air bubbles. 3. Injection Site Choose the area where skin is less tight, such as the upper arm, thigh, buttock and abdomen, etc. To avoid tissue damage, choose a site for each injection that is at least 1 cm from the previous injection site. 4. Injection Method Cleanse the skin with alcohol where the injection is to be made. Put the needle in such a position as to form 45° angle with the skin. Puncture the needle into skin and inject insulin. Then pull the needle out and apply gentle pressure over the injected site for several seconds. Do not rub the injection site. DOSAGE The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor's instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. ADVERSE EFFECT Hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. Few cases of the allergic reaction such as red and swollen or itching are reported. It usually disappears in a few days. In some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. CONTRAINDICATION Hypoglycemia or the patients who have allergic reaction to insulin or any of the excipients. PRECAUTION Inadequate dosing or discontinuation especially in type 1 diabetes, may lead to hyperglycemia. Hypoglycemia may occur if the insulin dose is too high in relation to the insulin requirement. Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycemia. PREGNANCY AND LACTATION There are no restrictions on treatment of diabetes with insulin during pregnancy, as ..
Tk.195.00/=
Ansulin R 40 IU
Indication: Type 1 and Type 2 Diabetes Mellitus. Dosage & Administration The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. PHARMACOLOGY Ansulin® is human insulin made by DNA recombinant technology so it has the same structure and function as natural insulin. The product can regulate the glucose metabolism and stimulate the ingestion and utilization of glucose by liver, muscles, and fat tissue. It can accelerate the transformation from glucose to glycogen stored in muscles and liver and inhibit the gluconeogenesis, thus, to lower the blood glucose. Normally, Ansulin® R takes effect within 30 minutes after injection, reaches its peak within 1-3 hours and lasts about 4-8 hours. On the other hand, Ansulin® N comes into effect slowly after injection, reaches its peak within 6-9 hours & lasts about 24 hours. Ansulin® 30/70 & Ansulin® 50/50 take effect within 30 minutes after injection, reach their peaks within 2-8 hours and last about 24 hours. USAGE 1. Ansulin® should be injected subcutaneously 15 minutes to one hour before meal. The exact time for administration is suggested by doctors with regard to each individual's case. 2. Prepare before use Firstly, clean your hands. Shake or rotate the vial gently to mix the solution uniformly and check if the insulin has the normal appearance. If using a new Ansulin® bottle then flip off the plastic protective cap and wipe the rubber stopper with an alcohol swab. Draw air into your syringe equal to the amount of insulin needed. Puncture the needle into the vial and inject the air. Turn the bottle and syringe upside down. Withdraw correct dose of insulin into the syringe. Before pulling out the needle, check if there are any bubbles remain in the syringe. If so, put the syringe upright and tap the syringe to discharge the air bubbles. 3. Injection Site Choose the area where skin is less tight, such as the upper arm, thigh, buttock and abdomen, etc. To avoid tissue damage, choose a site for each injection that is at least 1 cm from the previous injection site. 4. Injection Method Cleanse the skin with alcohol where the injection is to be made. Put the needle in such a position as to form 45° angle with the skin. Puncture the needle into skin and inject insulin. Then pull the needle out and apply gentle pressure over the injected site for several seconds. Do not rub the injection site. DOSAGE The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor's instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day. ADVERSE EFFECT Hypoglycemia is the most common adverse effect during insulin treatment and symptoms of hypoglycemia may occur suddenly. Few cases of the allergic reaction such as red and swollen or itching are reported. It usually disappears in a few days. In some instances, the allergy may be caused by other reasons rather than insulin, such as disinfectant and poor injection technique. CONTRAINDICATION Hypoglycemia or the patients who have allergic reaction to insulin or any of the excipients. PRECAUTION Inadequate dosing or discontinuation especially in type 1 diabetes, may lead to hyperglycemia. Hypoglycemia may occur if the insulin dose is too high in relation to the insulin requirement. Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycemia. PREGNANCY AND LACTATION There are no restrictions on treatment of diabetes with insulin during pregnancy, as insulin does not pass the placental barrier. Insulin treatment of the nursing moth..
Tk.195.00/=
Humalog Mix 75/25 KwikPen
75% insulin lispro protamine suspension / 25% insulin lispro injection ( rDNA orgine )..
Tk.1,000.00/=
Maxsulin 30/70 (100 IU)
Maxsulin 30/70 injection 100 IU: Each ml suspension contains Human Insulin (rDNA) BP 100 IU (equivalent to 3.47 mg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin (NPH).DescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.415.00/=
Maxsulin 30/70 (40 IU)
Maxsulin 30/70 injection 40 IU: Each ml suspension contains Human Insulin (rDNA) BP 40 IU (equivalent to 1.388 mg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin (NPH).DescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.195.00/=
Maxsulin 30/70 penset
Maxsulin 30/70 pensetDescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.222.00/=
Maxsulin 50/50 (100 IU)
Maxsulin 50/50 injection 100 IU: Each ml suspension contains Human Insulin (rDNA) BP 100 IU (equivalent to 3.47 mg) as 50% soluble Insulin (Regular) and 50% Isophane Insulin (NPH).DescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.415.00/=
Maxsulin 50/50 penset
Maxsulin 50/50 PenSet injection 100 IU: Each ml suspension contains Human Insulin (rDNA) BP 100 IU (equivalent to 3.47 mg) as 50% soluble Insulin (Regular) and 50% Isophane Insulin (NPH).DescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.222.00/=
Maxsulin N 100
Maxsulin N 100DescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.415.00/=
Maxsulin N 40 IU
Maxsulin N 40 IU InjDescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.195.00/=
Maxsulin R 100iu
Maxsulin R PenSet injection 100 IU: Each ml solution contains Human Insulin (rDNA) BP 100 IU (equivalent to 3.47 mg) as soluble Insulin (Regular).DescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.415.00/=
Maxsulin R 40 iu
Maxsulin R 40 iuDescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.195.00/=
Maxsulin R penset
Maxsulin R pensetDescriptionThe blood glucose lowering effect of Insulin is due to the facilitated uptake of glucose following binding of Insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.IndicationsTreatment of diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.Instructions to be given to the patientBefore injecting this Insulin,1. Disinfect the rubber stopper.2. If suspension, roll the vial between the palms of the hands until the liquid is uniformly white and cloudy.3. Draw into the syringe the same amount of air as the dose of insulin to be injected.4. Inject the air into the vial.5. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.6. Inject immediately.Dosage & AdministrationDosage is individualized and determined by the physician in accordance with the needs of the patient.The average range of total daily Insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, but can be much lower during the period of partial remission. In Insulin resistance, e.g. during puberty or due to obesity, the daily Insulin requirement may be substantially higher.Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day.An injection should be followed by a meal or snack containing carbohydrates within 30 minutes.The preparations are administered subcutaneously in the thigh or abdominal wall. A subcutaneous injectioninto the abdominal wall results in a faster absorption than from other injection sites.Insulin suspensions are never to be administered intravenously.Side EffectsHypoglycaemia, severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.Injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with Insulin. Most reactions are transitory and disappear during continued treatment. Oedema may occur upon initiation of Insulin therapy. These symptoms are usually of transitory nature.PrecautionsInadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia. In type 1 diabetes, untreated hyperglycaemic events eventually leads to diabetic ketoacidosis which is potentially lethal.Hypoglycaemia may occur if the Insulin dose is too high in relation to the Insulin requirement. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.Patients whose blood glucose control is greatly improved e.g. by intensified Insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.Use in Pregnancy & LactationThere are no restrictions on the treatment of diabetes with Insulin during pregnancy as Insulin does not pass the placental barrier.There are no restrictions on the treatment of diabetes with Insulin during lactation, as Insulin treatment of the nursing mother involves no risk to the baby. However, the Insulin dosage, diet or both may need to be reduced.Over DoseInsulins have no specific overdose definitions. However, hypoglycaemia may develop over sequential stages:Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carry some sugar lumps, sweets, biscuits or sugary fruit juice.Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given i.v, if the patient does not respond to glucagon within 10 to 15 minutes.Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.StorageStore at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light...
Tk.220.00/=
-140x140.jpg "Vibrenta Insulin")
Vibrenta Insulin
Vibrenta InsulinDescriptionVibrenta (Insulin glargine [rDNA] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. Vibrenta is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism.Primary function of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, primarily by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain.IndicationsVibrenta is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.Dosage & AdministrationVibrenta exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing. Potency of insulin glargine is approximately the same as human insulin.Vibrenta is recommended for once daily subcutaneous administration & may be administered at any time during the day. However, once started should be administered at the same time every day. The dose of Vibrenta must be individualized based on clinical response. Blood glucose monitoring is essential in all patients with diabetes. In patients with type 1 diabetes, Vibrenta must be used in regimens with short-acting insulin. Vibrenta is not recommended for intravenous administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia.Injection sites should be rotated within the same region (abdomen, thigh, or deltoid) from one injection to the next.Initiation of Vibrenta therapyThe recommended starting dose of Vibrenta in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements.The recommended starting dose of Vibrenta in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient\'s needs.Converting to Vibrenta from other insulin therapiesIf changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with Vibrenta, the amount and timing of shorter-acting insulins and doses of any oral anti-diabetic drugs may need to be adjusted.If transferring patients from once-daily NPH insulin to once-daily Vibrenta, the recommended initial Vibrenta dose is the same as the dose of NPH that is being discontinuedIf transferring patients from twice-daily NPH insulin to once-daily Vibrenta, the recommended initial Vibrenta dose is 80% of the total NPH dose that is being discontinuedInstructions to be given to the patientVialBefore injecting this Insulin:1. Disinfect the rubber stopper.2. Draw into the syringe the same amount of air as the dose of insulin to be injected.3. Inject the air into the vial.4. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.5. Inject immediately.CartridgeBefore injecting this Insulin:1. According to the instruction given with ConviPen, insert the Vibrenta cartridge into the pen correctly & equip the needle2. Remove the needle cap, discharge air bubbles in the catridge3. Adjust the dosage button to get correct dose & inject to the specific site4. In order to avoid cross contamination, do not let the needle touch anything during the process of preparation.For detail description, please see the Patient Instruction Leaflet provided with ConviPen.Side EffectsSide effects of Insulin glargine are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash.PrecautionsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision.Administration: Insulin glargine must not be diluted or mixed with any other insulin or solution. It should not be administered subcutaneously via an insulin pump or intravenously because severe hypoglycemia can occur.Renal or hepatic impairment: Reduction in the Insulin glargine dose may require in these cases.Use in Pregnancy & LactationPregnancy: Pregnancy category C. Insulin glargine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation: It is unknown whether insulin glarg..
Tk.600.00/=
Vibrenta Penset
Vibrenta PensetDescriptionVibrenta (Insulin glargine [rDNA] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. Vibrenta is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism.Primary function of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, primarily by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain.IndicationsVibrenta is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.Dosage & AdministrationVibrenta exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing. Potency of insulin glargine is approximately the same as human insulin.Vibrenta is recommended for once daily subcutaneous administration & may be administered at any time during the day. However, once started should be administered at the same time every day. The dose of Vibrenta must be individualized based on clinical response. Blood glucose monitoring is essential in all patients with diabetes. In patients with type 1 diabetes, Vibrenta must be used in regimens with short-acting insulin. Vibrenta is not recommended for intravenous administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia.Injection sites should be rotated within the same region (abdomen, thigh, or deltoid) from one injection to the next.Initiation of Vibrenta therapyThe recommended starting dose of Vibrenta in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements.The recommended starting dose of Vibrenta in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient\'s needs.Converting to Vibrenta from other insulin therapiesIf changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with Vibrenta, the amount and timing of shorter-acting insulins and doses of any oral anti-diabetic drugs may need to be adjusted.If transferring patients from once-daily NPH insulin to once-daily Vibrenta, the recommended initial Vibrenta dose is the same as the dose of NPH that is being discontinuedIf transferring patients from twice-daily NPH insulin to once-daily Vibrenta, the recommended initial Vibrenta dose is 80% of the total NPH dose that is being discontinuedInstructions to be given to the patientVialBefore injecting this Insulin:1. Disinfect the rubber stopper.2. Draw into the syringe the same amount of air as the dose of insulin to be injected.3. Inject the air into the vial.4. Turn the vial and syringe upside down and draw the correct insulin dose into the syringe. Withdraw the needle from vial and expel the air from the syringe and check that the dose is correct.5. Inject immediately.CartridgeBefore injecting this Insulin:1. According to the instruction given with ConviPen, insert the Vibrenta cartridge into the pen correctly & equip the needle2. Remove the needle cap, discharge air bubbles in the catridge3. Adjust the dosage button to get correct dose & inject to the specific site4. In order to avoid cross contamination, do not let the needle touch anything during the process of preparation.For detail description, please see the Patient Instruction Leaflet provided with ConviPen.Side EffectsSide effects of Insulin glargine are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash.PrecautionsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision.Administration: Insulin glargine must not be diluted or mixed with any other insulin or solution. It should not be administered subcutaneously via an insulin pump or intravenously because severe hypoglycemia can occur.Renal or hepatic impairment: Reduction in the Insulin glargine dose may require in these cases.Use in Pregnancy & LactationPregnancy: Pregnancy category C. Insulin glargine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation: It is unknown whether insulin glargi..
Tk.600.00/=
Actrapid 100 IU penfill
3 ml cartridge: ৳ 419.00 (5's pack: ৳ 2,095.00)Actrapid is a fast-acting insulin. This means that it will start to lower your blood sugar about half an hour after you take it, and the effect will last for approximately 8 hours. Actrapid is often given in combination with longer-acting insulin products.How to use this insulinActrapid is for injection under the skin (subcutaneously). Always vary the sites you inject, to avoid lumps (see 5 Possible side effects). The best places to give yourself an injection are: the front of your waist (abdomen); your buttocks; the front of your thighs or upper arms. Your insulin will work more quickly if you inject it around the waist.IndicationsTreatment of all patients with type 1 diabetes. Treatment of patients with type 2 diabetes who are not adequately controlled by diet and/ or oral hypoglycemic agents. For the initial stabilization of diabetes in patients with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome and during periods of stress such as severe infections and major surgery in diabetic patients. Treatment of gestational diabetes...
Tk.419.00/=
Actrapid 100 IU (1 vial)
Actrapid is a fast-acting insulin. This means that it will start to lower your blood sugar about half an hour after you take it, and the effect will last for approximately 8 hours. Actrapid is often given in combination with longer-acting insulin products.How to use this insulinActrapid is for injection under the skin (subcutaneously). Always vary the sites you inject, to avoid lumps (see 5 Possible side effects). The best places to give yourself an injection are: the front of your waist (abdomen); your buttocks; the front of your thighs or upper arms. Your insulin will work more quickly if you inject it around the waist.Actrapid vials are for use with insulin syringes with the corresponding unit scale.Actrapid may also be administered intravenously in special situations by medical professionals.How to inject Actrapid on its own1. Draw air into the syringe, in the same amount as the dose of insulin you need2. Inject the air into the vial: push the needle through the rubber stopper and press the plunger3. Turn the vial and syringe upside down4. Draw the right dose of insulin into the syringe5. Pull the needle out of the vial6. Make sure there is no air left in the syringe: point the needle upwards and push the air out7. Check you have the right dose8. Inject straight away...
Tk.415.00/=
Actrapid 40 IU (1 vial)
Actrapid is a fast-acting insulin. This means that it will start to lower your blood sugar about half an hour after you take it, and the effect will last for approximately 8 hours. Actrapid is often given in combination with longer-acting insulin products.How to use this insulinActrapid is for injection under the skin (subcutaneously). Always vary the sites you inject, to avoid lumps (see 5 Possible side effects). The best places to give yourself an injection are: the front of your waist (abdomen); your buttocks; the front of your thighs or upper arms. Your insulin will work more quickly if you inject it around the waist. Actrapid vials are for use with insulin syringes with the corresponding unit scale. Actrapid may also be administered intravenously in special situations by medical professionals.To inject Actrapid on its own1. Draw air into the syringe, in the same amount as the dose of insulin you need2. Inject the air into the vial: push the needle through the rubber stopper and press the plunger3. Turn the vial and syringe upside down4. Draw the right dose of insulin into the syringe5. Pull the needle out of the vial6. Make sure there is no air left in the syringe: point the needle upwards and push the air out7. Check you have the right dose8. Inject straight away...
Tk.285.00/=
Ansulin 30/70 (100 IU/ml) Pen Cartridge
Indication: Type 1 and Type 2 Diabetes Mellitus.Dosage & Administration:The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day...
Tk.222.00/=
Ansulin 50/50 (100 IU/ml) Pen Cartridge
Indication: Type 1 and Type 2 Diabetes Mellitus.Dosage & Administration:The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day...
Tk.222.00/=
Ansulin R (100 IU/ml) Pen Cartridge
Indication: Type 1 and Type 2 Diabetes Mellitus.Dosage & Administration:The dosage form, the dosage and the administration time of the insulin are different due to the individual differences of each patient. In addition, the dosage is also affected by food, working style and exercising intensity. Therefore, patients should use the insulin under doctor\'s instruction. The average range of total daily insulin requirement for maintenance therapy in type 1 diabetic patients lies between 0.5 and 1.0 IU/kg. In pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg, whereas in insulin resistant cases, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetic patients are often lower, e.g. 0.3 to 0.6 IU/kg/day...
Tk.220.00/=
AnsuPen (Per Box: 1 Device)
Indication: AnsuPen™ can deliver doses from 1 to 60 units, in increments of 1 unit. It is designed to be used with 3ml Ansulin™ pen cartridges. ..
Tk.700.00/=
diasulin 50%+50% in 40 IU/10 ml vial injection
diasulin 50%+50% in 40 IU/10 ml vial injection..
Tk.195.00/=
Humalog Kwikpen 100u/ml, 3 ml Pre-filled pens
Humalog Kwikpen 100u/ml, 3ml 5x3ml Pre-filled pens..
Tk.870.00/=
Humalog mix50/50 Kwikpen 100u/ml, 3 ml Pre-filled pens
Humalog mix50/50 Kwikpen100u/ml, 3 ml 5x3ml Pre-filledpens..
Tk.1,347.00/=
Humulin70/30 100 iu/ 10 ml Vial
HUMULIN 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]) is a human insulin suspension. Human insulin is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. HUMULIN 70/30 is a suspension of crystals produced from combining human insulin and protamine sulfate under appropriate conditions for crystal formation and mixing with human insulin injection. The amino acid sequence of HUMULIN 70/30 is identical to human insulin and has the empirical formula C257H383N65O77S6 with a molecular weight of 5808.HUMULIN 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]) is a human insulin suspension.Human insulin is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. HUMULIN 70/30 is a suspension of crystals produced from combining human insulin and protamine sulfate under appropriate conditions for crystal formation and mixing with human insulin injection. The amino acid sequence of HUMULIN 70/30 is identical to human insulin and has the empirical formula C257H383N65O77S6 with a molecular weight of 5808...
Tk.750.00/=
Buy Insulin in Bangladesh
Most patients who have type 1 diabetes and few people who have type 2 diabetes require to inject insulin to assist maintain their blood glucose levels. The aim of injecting insulin is to maintain your blood sugar level in a healthy range as much as achievable. Insulin can't be used via the mouth; always it is needed to be injected via an injection.
Diabetes Store is a perfect online shop to buy Insulin items in Bangladesh such as Insulin pen, Insulin injection. We only deal with highly trusted, reliable, and trusted Insulin to make our clients available with perfect medication in dealing with their diabetes.
You need not to require any medical prescription for ordering the Insulin in Bangladesh. Just on a single tap, you can get the Insulin to your doorsteps. We deliver quality rich and highly proven Insulin to help you manage your body glucose (sugar) by supporting your cells in consuming glucose.